BioCryst Pharmaceuticals (BCRX) gains on new contract
BioCryst Pharmaceuticals (NASDAQ: BCRX) shares gained 0.3% to $6.54 after the company was awarded a contract by the National Institute of Allergy and Infectious Diseases to develop BCX4430 for the treatment of Marburg virus disease. Share volume was 562,000, compared to an all-day average of 2.5 million
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here